Efecto de una dieta rica en calcio sobre el metabolismo mineral y óseo en ratas / Effect of a calcium-rich diet on bone and mineral metabolism in rats

Objetivo: Una dieta rica en calcio se ha recomendado generalmente para mantener una adecuada salud ósea; no obstante, estudios recientes han despertado la controversia sobre sus beneficios. En este sentido, la mayoría de los estudios existentes en modelos animales están realizados con dietas deficientes en vitamina D. En este estudio se evaluará el efecto de una dieta rica en calcio sobre el metabolismo mineral y la histomorfometría ósea en rata. Además, en células UMR-106 se evaluó el efecto directo del suplemento de calcio sobre la expresión de genes osteogénicos.Material y métodos: Un grupo de ratas wistar macho de aproximadamente 3 meses de edad fue alimentado con dieta de contenido normal de calcio (0,6%) mientras que otro grupo se alimentó con dieta de alto contenido en calcio (1,2%). Transcurridos 20 días se recogieron muestras de orina 24h, sangre para análisis bioquímicos y el fémur para estudio de histomorfometría ósea. In vitro, se estudió la expresión génica de Runx2, Osterix y Osteocalcina en células UMR-106 cultivadas en condiciones de alto contenido en calcio.Resultados: La ingesta de una dieta rica en calcio redujo la concentración de PTH y calcitriol en plasma, aumentó la calciuria y disminuyó la fosfaturia. A nivel óseo, se observó una drástica disminución de la actividad osteoblástica consistente con la bajada de PTH; sin embargo, el volumen trabecular permaneció similar en ambos grupos. In vitro, el suplemento de calcio no disminuyó la expresión de marcadores osteoblásticos en UMR-106, indicando que los efectos in vivo son mayormente indirectos y debidos a la bajada de PTH.Conclusiones: Una dieta de alto contenido en calcio reduce la concentración de PTH y calcitriol en plasma, resultando en una disminución de la actividad osteoblástica. (AU)

Nivel de información sobre protectores bucales y avulsión dentaria en entrenadores deportivos

Introducción:La práctica deportiva conlleva un alto riesgo de traumatismos dentoalveolares, por lo que es necesario que los entrenadores y deportistas conozcan sobre el uso adecuado de los protectores bucales y el procedimiento de urgencia ante la aparición de un trauma dental.Objetivo:Determinar el nivel de información sobre protectores bucales y avulsión dentaria en entrenadores deportivos.Métodos:Se realizó un estudio descriptivo de corte transversal, durante el mes de febrero de 2020, en la Escuela de Iniciación Deportiva Escolar Provincial Lino Salabarría Pupo de Sancti Spíritus. Para ello se seleccionó una muestra probabilística, representativa y aleatoria de 25 entrenadores de los deportes de combate y juego con pelotas, a los cuales se le aplicó una encuesta estructurada sobre protectores bucales y avulsión dentaria.Resultados:Entre los integrantes de la serie, 76 Pociento eran universitarios y 52 Pociento poseían más de 10 años de experiencia profesional. Asimismo, se obtuvo que 88 Pociento recomendaran el uso del protector bucal a sus deportistas, pero la mayoría desconocía sus características, funciones y tipos, así como la conducta a seguir ante la ocurrencia de una avulsión dentaria.Conclusiones:El nivel de información sobre protectores bucales y avulsión dentaria en los entrenadores deportivos fue deficiente, lo que demostró que es necesaria la educación en dicho tema. De hecho, los estomatólogos tienen la tarea de realizar campañas para incentivar y educar en el uso de los protectores bucales y en el procedimiento correcto de urgencia si ocurriera un trauma dentoalveolar.[AU]

Serum Magnesium is associated with Carotid Atherosclerosis in patients with high cardiovascular risk (CORDIOPREV Study).

This study aimed to ascertain whether there is an independent association between serum magnesium (Mg) and the Carotid Intima-Media Thickness (IMT-CC), a well-accepted atherosclerotic-biomarker surrogate of cardiovascular disease (CVD), in a population with high cardiovascular risk. Serum Mg and traditional atherosclerotic risk factors were recorded in 939 patients (mean age, 59.6 ± 0.3 years, 83.2% men) with coronary heart disease (CHD) enrolled in the CORDIOPREV trial. Serum Mg strongly associated with IMT-CC. Before adjusting for potential confounding factors, IMT-CC decreased by 0.111 ± 0.011 mm per mg/dl increase in serum Mg (p < 0.001). After adjustment, the effect of Mg did not appear mediated through factors related to glucose metabolism, the lipid profile or the mineral metabolism and renal function. Multivariate models showed the lower Mg levels (quartile 1) as a strong independent factor contributing to IMT-CC along with age, sex, SBP, HDL-C, and diuretic use. Logistic regression analysis confirmed the predictive ability of serum Mg to differentiate patients at higher atherosclerotic risk as defined by an IMT-CC ≥ 1.0 mm, yielding a OR for the lower quartile of 10.623 (95%CI 2.311-48.845; P = 0.002) and a ROC-derived cutoff of 1.61 mg/dl. Therefore, our findings outline low serum magnesium as a possible independent risk factor for carotid atherosclerosis.

Vitamin D modulates tissue factor and protease-activated receptor 2 expression in vascular smooth muscle cells.

Clinical and epidemiologic studies reveal an association between vitamin D deficiency and increased risk of cardiovascular disease. Because vascular smooth muscle cell (VSMC)-derived tissue factor (TF) is suggested to be critical for arterial thrombosis, we investigated whether the vitamin D molecules calcitriol and paricalcitol could reduce the expression of TF induced by the proinflammatory cytokine TNF-α in human aortic VSMCs. We found that, compared with controls, incubation with TNF-α increased TF expression and procoagulant activity in a NF-κB-dependent manner, as deduced from the increased nuclear translocation of nuclear factor κ-light-chain-enhancer of activated B cells protein 65 (p65-NF-κB) and direct interaction of NF-κB to the TF promoter. This was accompanied by the up-regulation of TF signaling mediator protease-activated receptor 2 (PAR-2) expression and by the down-regulation of vitamin D receptor expression in a miR-346-dependent way. However, addition of calcitriol or paricalcitol blunted the TNF-α-induced TF expression and activity (2.01 ± 0.24 and 1.32 ± 0.14 vs. 3.02 ± 0.39 pmol/mg protein, P < 0.05), which was associated with down-regulation of NF-κB signaling and PAR-2 expression, as well as with restored levels of vitamin D receptor and enhanced expression of TF pathway inhibitor. Our data suggest that inflammation promotes a prothrombotic state through the up-regulation of TF function in VSMCs and that the beneficial cardiovascular effects of vitamin D may be partially due to decreases in TF expression and its activity in VSMCs.

Angiotensin II prevents calcification in vascular smooth muscle cells by enhancing magnesium influx.

BACKGROUND: Vascular calcification (VC) is highly prevalent in patients with chronic kidney disease (CKD). Low magnesium levels are associated with VC, and recent in vitro studies confirm a protective role of magnesium, which is mediated by its entry into the VSMCs through the Transient Receptor Potential Melastatin 7 (TRPM7) channel. The role of Angiotensin II (Ang II) on VC is still unclear. As Ang II is able to stimulate TRPM7 activity, we hypothesize that it might prevent VC. Thus, the aim of this study was to dissect the direct effect of Ang II on VC. MATERIALS AND METHODS: We worked with a model of high phosphate (HP)-induced calcification in human aortic smooth muscle cells, which resembles the CKD-related VC. RESULTS: Addition of Ang II to cells growing in HP decreased calcification, which was associated with the upregulation of the osteogenic factors BMP2, Runx2/Cbfa1, Osterix and ALP. A reduction of magnesium entry into the HP-calcifying cells was found. The treatment with Ang II avoided this reduction, which was reversed by the cotreatment with the TRPM7-inhibitor 2-APB. The protective effect of Ang II was related to AT1R-induced ERK1/2 MAPKinase activation. HP-induced calcification was also associated with the upregulation of the canonical Wnt/beta-catenin pathway, while its downregulation was related to attenuation of calcification by Ang II. CONCLUSION: As hypothesized, Ang II prevented phosphate-induced calcification in VSMCs, which appears mediated by the increase of magnesium influx and by the activation of the ERK1/2 and the inhibition of the canonical Wnt/beta-catenin signalling pathways.

Vitamin D and vascular calcification in chronic kidney disease.

Vascular calcification is common in patients with chronic kidney disease (CKD) and contributes to the increased rate of cardiovascular morbidity and mortality. The mechanisms regulating vascular calcification are under investigation; it is accepted that vascular calcification is an active and complex process involving many factors that promote or inhibit calcification. Vascular smooth muscle cells undergo transformation into osteogenic cells. This transformation is being stimulated by high phosphate, and more recently the role of the calcium phosphate nanocrystals has gained attention. Experimental models of uremia and in vitro studies have shown that an excess of calcitriol accelerates vascular calcification. However, observational studies suggest that vitamin D provides a survival advantage for patients with CKD. Experimental work shows that for similar serum concentrations of calcium and phosphate paricalcitol produces less vascular calcification than calcitriol suggesting a differential effect at the cellular level. Important issues regarding the role of vitamin D compounds on vascular calcification will be commented in this review.

Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo.

Fibroblastic growth factor 23 (FGF23) is a bone-derived hormone that has a pivotal role in the pathogenesis of mineral disorders in chronic kidney disease. To study the effect of parathyroid hormone (PTH) on FGF23, rats were parathyroidectomized for a week and then implanted with constant-delivery infusion pumps to provide vehicle, a physiological, or a threefold supraphysiological dose of parathyroid hormone. Parathyroidectomy resulted in a significant decrease in blood ionized calcium, FGF23, and calcitriol along with an increase in phosphorus concentrations. PTH replacement produced a dose-dependent increase in ionized calcium and FGF23 with decreased phosphorus. Calcitriol was also increased but there was no dose effect of PTH treatment. To maintain normal plasma calcitriol levels, two additional groups of parathyroidectomized rats were given calcitriol and temporarily treated with vehicle or the supraphysiological dose of PTH. FGF23 was significantly increased by calcitriol in the vehicle-treated rats but was not further increased above that in rats given the supraphysiological dose of PTH in the absence of calcitriol. Klotho expression in the kidney decreased after parathyroidectomy but was restored by hormone supplementation. Hence, our results show a direct and an indirect effect of PTH on FGF23 secretion, the latter through changes in calcitriol concentrations.

FGF23 fails to inhibit uremic parathyroid glands.

Fibroblast growth factor 23 (FGF23) modulates mineral metabolism by promoting phosphaturia and decreasing the production of 1,25-dihydroxyvitamin D(3). FGF23 decreases parathyroid hormone (PTH) mRNA and secretion, but despite a marked elevation in FGF23 in uremia, PTH production increases. Here, we investigated the effect of FGF23 on parathyroid function in normal and uremic hyperplastic parathyroid glands in rats. In normal parathyroid glands, FGF23 decreased PTH production, increased expression of both the parathyroid calcium-sensing receptor and the vitamin D receptor, and reduced cell proliferation. Furthermore, FGF23 induced phosphorylation of extracellular signal-regulated kinase 1/2, which mediates the action of FGF23. In contrast, in hyperplastic parathyroid glands, FGF23 did not reduce PTH production, did not affect expression of the calcium-sensing receptor or vitamin D receptor, and did not affect cell proliferation. In addition, FGF23 failed to activate the extracellular signal-regulated kinase 1/2-mitogen-activated protein kinase pathway in hyperplastic parathyroid glands. We observed very low expression of the FGF23 receptor 1 and the co-receptor Klotho in uremic hyperplastic parathyroid glands, which may explain the lack of response to FGF23 in this tissue. In conclusion, in hyperparathyroidism secondary to renal failure, the parathyroid cells resist the inhibitory effects of FGF23, perhaps as a result of the low expression of FGF23 receptor 1 and Klotho in this condition.